Teva (TEVA) investors approve director, executive pay and auditor at 2026 meeting
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Teva Pharmaceutical Industries Limited reported results of its annual shareholder meeting held on May 28, 2026. Shareholders elected Dr. Sol J. Barer to the Board to serve until the 2029 annual meeting, with 627,816,662 votes for and 245,921,571 against.
Shareholders also approved, on a non-binding advisory basis, the compensation of Teva’s named executive officers, with 795,976,042 votes for and 77,082,847 against. In addition, they approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as independent registered public accounting firm through the 2027 annual meeting.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Director election - For: 627,816,662 votes
Director election - Against: 245,921,571 votes
Say-on-pay - For: 795,976,042 votes
+3 more
6 metrics
Director election - For
627,816,662 votes
Votes for election of Dr. Sol J. Barer to Board until 2029 meeting
Director election - Against
245,921,571 votes
Votes against election of Dr. Sol J. Barer
Say-on-pay - For
795,976,042 votes
Non-binding advisory approval of named executive officer compensation
Say-on-pay - Against
77,082,847 votes
Votes against executive compensation package
Auditor approval - For
880,542,242 votes
Approval of Kesselman & Kesselman as independent registered public accounting firm
Auditor approval - Against
36,085,507 votes
Votes against Kesselman & Kesselman as auditor
Key Terms
Annual Meeting, non-binding advisory basis, named executive officers, independent registered public accounting firm, +1 more
5 terms
Annual Meeting regulatory
"Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) held its Annual Meeting on May 28, 2026"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
non-binding advisory basis regulatory
"The shareholders approved, on a non-binding advisory basis, the compensation for Teva’s named executive officers"
A non-binding advisory basis is guidance or a recommendation offered for informational purposes that does not create legal obligations or guarantees; recipients can accept, modify, or ignore it without contractual consequences. Investors should treat it like a weather forecast for planning—useful for forming expectations and assessing risk, but not a firm promise—so they should verify assumptions, seek confirming information, and avoid relying on it as the sole basis for investment decisions.
named executive officers financial
"the compensation for Teva’s named executive officers listed in the proxy statement for the Annual Meeting"
Named executive officers are the senior company leaders whose names, roles and compensation are singled out in required regulatory filings; this typically includes the chief executive, chief financial officer and the next highest‑paid senior officers. Investors treat this list like a team roster — it shows who makes key decisions, how they are paid and whether incentives align with shareholder interests, so changes or pay patterns can signal governance quality, risk or strategic shifts.
independent registered public accounting firm regulatory
"approved the appointment of Kesselman & Kesselman ... as Teva’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
broker non-votes regulatory
"Broker non-votes 795,976,042 | | 77,082,847 | | 1,170,026 | | 50,661,570"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
FAQ
What were broker non-votes on Teva (TEVA) proposals at the 2026 annual meeting?
Broker non-votes totaled 50,661,570 shares on both the director election and the advisory vote on executive compensation. There were zero broker non-votes on the appointment of Kesselman & Kesselman as Teva’s independent registered public accounting firm.